Celldex Therapeutics
CLDX
171 hedge funds and large institutions have $1.34B invested in Celldex Therapeutics in 2025 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 64 increasing their positions, 53 reducing their positions, and 31 closing their positions.
21% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 53
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.15% less ownership
Funds ownership: 111.07% → 110.92% (-0.15%)
10% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 31
2% less funds holding
Funds holding: 174 → 171 (-3)
28% less capital invested
Capital invested by funds: $1.86B → $1.34B (-$525M)
65% less call options, than puts
Call options by funds: $2.13M | Put options by funds: $6.12M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
+$71.5M |
| 2 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$32.1M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$24.1M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$11.7M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$10.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JFG
Jefferies Financial Group
New York
|
-$52.2M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$42.9M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$18.4M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$13.9M |
| 5 |
Goldman Sachs
New York
|
-$11.3M |
CLDX Hedge Fund Activity: Q1 2025 in Review
171 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q1 2025, worth a combined $1.34B — down 28% from $1.86B a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of CLDX and 28 opened new positions — a net loss of 3 holders — while 53 trimmed existing stakes and 64 added.
The largest buyer was Commodore Capital, opening a new position worth an estimated $71.5M. The largest seller was Jefferies Financial Group, cutting an estimated $52.2M.
- 171 institutional investors held Celldex Therapeutics (CLDX) as of Q1 2025, down from 174 in Q4 2024.
- Funds reported $1.34B of Celldex Therapeutics stock for Q1 2025, down 28% quarter-over-quarter.
- 28 funds opened new Celldex Therapeutics positions in Q1 2025 and 31 closed out, a net change of -3 holders.
- The largest Celldex Therapeutics buyer in Q1 2025 was Commodore Capital, an estimated $71.5M added.
- The largest Celldex Therapeutics seller in Q1 2025 was Jefferies Financial Group, an estimated $52.2M sold.
Based on aggregated 13F filings for Q1 2025.